Drugs Made In America Acquisition Corp.
DMAA
$10.54
$0.000.00%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.82M | 1.01M | 887.60K | 755.70K | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.82M | 1.01M | 887.60K | 755.70K | -- |
| Operating Income | -2.82M | -1.01M | -887.60K | -755.70K | -- |
| Income Before Tax | 5.94M | 5.45M | 3.12M | 829.70K | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 5.94 | 5.45 | 3.12 | 0.83 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.94M | 5.45M | 3.12M | 829.70K | -- |
| EBIT | -2.82M | -1.01M | -887.60K | -755.70K | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.19 | 0.15 | 0.07 | 0.00 | -- |
| Normalized Basic EPS | 0.12 | 0.09 | 0.04 | 0.00 | -- |
| EPS Diluted | 0.19 | 0.15 | 0.06 | -0.01 | -- |
| Normalized Diluted EPS | 0.12 | 0.09 | 0.04 | 0.00 | -- |
| Average Basic Shares Outstanding | 126.01M | 100.40M | 75.45M | 41.93M | -- |
| Average Diluted Shares Outstanding | 126.73M | 101.11M | 76.17M | 42.65M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |